1772MO Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study - Concepedia

Concepedia

Publication | Open Access

1772MO Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study

DOI Full Paper Access

11

Citations

1

References

2023

Year

Christian Gratzke, Mustafa Özgüroğlu, A. Peer, Mehmet Alı Nahıt Şendur, Margitta Retz, J.C.H. Goh, Wolfgang Loidl, Gautam Jayram, S-S. Byun, Cheol Kwak,

Annals of Oncology

References

	Year	Citations

Page 1